VOGO 0.3MG contain Voglibose which belongs to a group of medicine called competitive α glucosisade inhibitors (α-GIs). It is indicated to improve postprandial hyperglycaemia in patients with type 2 diabetes mellitus.
Type 2 diabetes mellitus is a condition in which your body does not make enough insulin, and or the insulin produces does not work. When this happens, your body makes too much of sugar (i.e. glucose) which gets build up in the blood resulting in serious health problems.
Your blood sugar will be monitored by your doctor periodically, with regular blood test, including your blood sugar level and your hemoglobin A1C. Stay on exercise and diet as prescribed by your doctor while taking this medicine.
Before taking this medicine tell your doctor if you have ever had kidney disease, heart disease or pancreas problems. Pregnant or breastfeeding women should consult their doctor before taking this medicine.
It works by inhibiting the intestinal enzymes responsible for breaking complex sugars into simple sugars such as glucose. This prevents blood glucose levels from rising very high immediately after meals.
Always take VOGO 0.3MG exactly as your doctor has told you. This medicine must be taken start of a meal. Try to take VOGO 0.3MG at the same time each day. It should be swallowed whole with water. Do not crush or chew the medicine.
Diarrhoea:
Drink lot of fluid such as water or squash, to avoid dehydration. Do not take any other medicine without talking to a doctor.
Nausea and vomiting:
Keep try taking this medicine with, or just after, a meal or snack and stick to simple meals and do not eat rich or spicy food.
Dizziness:
Lying down and closing the eyes will help. Drink plenty of water and keep hydrated. Take plenty of sleep.
Constipation:
Take fibre rich foods such as fresh fruit, vegetables and cereals, and drink plenty of water. Exercise more regularly.
VOGO 0.3MG should be used with caution in pregnant women. Consult your doctor before taking this medicine.
VOGO 0.3MG should be used with caution in breast-feeding women. Consult your doctor before taking this medicine.
Consumption of alcohol is not recommended during treatment with VOGO 0.3MG.
VOGO 0.3MG should be used with caution in patients suffering from active kidney diseases. Consult your doctor for advice.
VOGO 0.3MG should be used with caution in patients suffering from liver function impairment or active liver diseases. Consult your doctor for advice.
Do not take VOGO 0.3MG if you are allergic (hypersensitive) to Voglibose or any other ingredients in this medicine.
Tell your doctor if you have or had condition such as,
Talk to your doctor if you are taking,
| Drug | : | Voglibose |
| Pharmacological Category | : | Oral antidiabetic agent |
| Therapeutic Indication | : | Postprandial hyperglycaemia inpatients with type 2 diabetes mellitus |
| Dosage Forms | : | Tablet, Dispersible tablet |
Store at room temperature and keep out of reach of children.
How does VOGO 0.3MG works?
It works by inhibiting the intestinal enzymes responsible for breaking complex sugars into simple sugars such as glucose. This prevents blood glucose levels from rising very high immediately after meals.
Can I take VOGO 0.3MG during pregnancy?
It should be used with caution in pregnant women. Consult your doctor before taking.
Can VOGO 0.3MG cause constipation?
Yes, this medicine may cause constipation in some individuals. Take fibre rich foods such as fresh fruit, vegetables and cereals, and drink plenty of water. Exercise more regularly.
1. KD Tripathi. Insulin, Oral Hypoglycaemic Drugs and Glucagon. Essentials of Medical Pharmacology. seventh edition.2013. Page-277.
2. Bertram G. Katzung, Pancreatic Hormones and Antidiabetic Drugs, Basic & Clinical Pharmacology, Fourteenth Edition, 2015. Page-761.
3. Ajay S. Dabhi,1 Nikita R. Bhatt,2 and Mohit J. Shah3. Voglibose: An Alpha Glucosidase Inhibitor.US National Library of Medicines, National Institutes of Health. 15 Dec 2013. [Accessed 30 Oct 2020] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3919386/#:~:text=So%20voglibose%3A,carbohydrate%20absorption%20and%20decreases%20PPHG
4. Ajay S Dabhi 1, Nikita R Bhatt 2, Mohit J Shah 3. Voglibose: an alpha glucosidase inhibitor. NIH: National Library of Medicine, National center of biotechnology Information Pubmed.gov. Dec 2013. [Accessed 30 Oct 2020] https://pubmed.ncbi.nlm.nih.gov/24551718/
5. Cipla med, August 2015 [Revised on August 2015] [Accessed 30 Oct 2020] https://www.ciplamed.com/content/prandial-md-tablets
The contents of this website are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Do not disregard professional medical advice or delay in seeking it because of something you have read on this website.